LUCI DAVID P 4
4 · Acurx Pharmaceuticals, Inc. · Filed Apr 22, 2026
Research Summary
AI-generated summary of this filing
Acurx (ACXP) CEO Luci David Receives Stock Option Award
What Happened Luci David, President, CEO and Director of Acurx Pharmaceuticals (ACXP), was granted stock options to purchase 37,100 shares on April 20, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 (no cash paid at grant). This is a compensation grant rather than an open‑market buy or sale.
Key Details
- Transaction (grant) date: 2026-04-20; Form 4 filed 2026-04-22 (timely).
- Instrument: Stock options to purchase 37,100 common shares (derivative transaction).
- Reported acquisition value on Form 4: $0.00 (common for option grants).
- Vesting: 36 equal monthly installments beginning on the grant date (per footnote).
- Shares owned after transaction: not specified in the filing.
Context This was an option award (future right to buy shares subject to vesting), not an exercise or sale. Such grants are routine executive compensation and do not indicate immediate buying or selling in the market.
Insider Transaction Report
Form 4
LUCI DAVID P
DirectorPresident and CEO
Transactions
- Award
Stock Option
[F1]2026-04-20+37,100→ 37,100 totalExercise: $2.36Exp: 2036-04-20→ Common Stock (37,100 underlying)
Footnotes (1)
- [F1]On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Signature
/s/ Kostantinos Skordalos, Power of Attorney for: David P. Luci|2026-04-22